MS & Immune Disorders

Filter Your Results




Stem-Cell Transplants Delayed Disease Progression of Multiple Sclerosis

Friday, January 25, 2019—January 25, 2019 -- As published in JAMA, interim results of the phase 2 MIST trial (NCT00273364) show that stem-cell treatment resulted in a significantly prolonged time…

Breakthrough Device Designation Granted to Brain-Monitoring Technology

Wednesday, January 09, 2019—The Food and Drug Administration has granted breakthrough device designation to a brain health monitoring technology (Neurametrix; San Francisco, CA). The approved use is moni…

Inebilizumab Meets Primary and Secondary Endpoints for Treatment of Neuromyelitis Optica Spectrum Disorder

Friday, January 04, 2019—In a global trial of inebilizumab (Viela Bio, Gaithersberg, MD) for the treatment of patients with neuromyelitis optica spectrum disorder (NMOSD), the drug met its primary and…

American Academy of Neurology Call for Uniformity in Brain Death Standards

Thursday, January 03, 2019—Noting that only 1 state, Nevada, has adopted legislation requiring use of medically accepted guidelines for determining brain death, the American Academy of Neurology (AAN) i…

Gray Matter Atrophy in Multiple Sclerosis May Occur Independently of Clinically Effective Treatment

Friday, December 21, 2018—Once thought to be a disease only of white matter, the myelin sheath of oligoglia, it is now accepted that multiple sclerosis (MS) affects nerve cells themselves, the gray mat…

New Drug Application Submitted for Therapy for Multiple Sclerosis

Tuesday, December 18, 2018—A New Drug Application (NDA) has been submitted to the US Food and Drug Administration (FDA) for diroximel fumarate (BIIB098/Vumerity; Alkermes PLC, Waltham, MA), a novel oral…

FDA Approves Amifampridine for Lambert-Eaton Myasthenic Syndrome

Monday, December 03, 2018—The FDA has approved amifampridine (Firdapse, Catalyst Pharmaceuticals, Coral Gables, FL) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. This…

Warning Issued for Possible Stroke Risk When Starting Alemtuzumab

Friday, November 30, 2018—The Food and Drug Administration (FDA) has issued a warning about possible risk of stroke and neurovascular injury for patients starting treatment with alemtuzumab (Lemtrada, …


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.